EU regulators come up with a surprise rejection of Biogen Idec's (BIIB -2.7%) multiple sclerosis...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

EU regulators come up with a surprise rejection of Biogen Idec's (BIIB -2.7%) multiple sclerosis drug Fampyra (Ampyra in the U.S.), which also knocks shares of the drug's developer Acorda Therapeutics (ACOR -16.7%).